Skip to main content
Premium Trial:

Request an Annual Quote

IP Roundup: California Institute of Technology, Affymetrix, Illumina, Immucor, Progenika Biopharma

Premium

Title: Microfluidic free interface diffusion techniques.
Patent Number: 8,709,152
Filed: Aug. 19, 2011
Lead Inventor: Carl Hansen, California Institute of Technology


Title: Analysis of methylation using nucleic acid arrays.
Patent Number: 8,709,716
Filed: Jan. 27, 2011
Lead Inventor: Yanxiang Cao, Affymetrix


Title: Generation of uniform fragments of nucleic acids using patterned substrates.
Patent Number: 8,709,717
Filed: April 2, 2010
Lead Inventor: Kevin Gunderson, Illumina


Title: Method of making an array of nucleic acid colonies.
Patent Number: 8,709,729
Filed: May 29, 2013
Lead Inventor: Mostafa Ronaghi, Illumina


Title: Analysis, secure access to, and transmission of array images.
Patent Number: 8,712,123
Filed: April 12, 2011
Lead Inventor: Xiongwu Xia, Immucor


Title: Methods of prognosing a rheumatoid arthritis remission phenotype.
Patent Number: 8,712,696
Filed: Nov. 2, 2009
Lead Inventor: Arrate Eguiara, Progenika Biopharma

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.